Dr. Reddy S Laboratories
Nifty 50
Nifty 100
Nifty 200
Nifty 500
LargeMid 250
F&O
₹1,165.50
+1.97%
Delayed · cached 15 min
Peer comparison
| Company | Price↕ | Market Cap↕ | P/E↕ | P/B↕ | ROE %↕ | ROCE %↕ | Div yield %↕ | Valuation |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Ind L | ₹ 1,840.00 | ₹ 4.41L Cr | 36.49 | 5.28 | 16.00 | 20.50 | 0.00 | Above FV |
| Divi S Laboratories Ltd | ₹ 9,322.00 | ₹ 2.47L Cr | 84.42 | 14.76 | 16.50 | 22.00 | 0.00 | Above FV |
| Torrent Pharmaceuticals L | ₹ 4,965.50 | ₹ 1.89L Cr | 79.31 | 20.03 | 27.40 | 15.20 | 0.00 | Above FV |
| Cipla Ltd | ₹ 1,366.00 | ₹ 1.10L Cr | 32.72 | 3.20 | 11.60 | 15.50 | 0.00 | Above FV |
| Zydus Lifesciences Ltd | ₹ 1,119.10 | ₹ 1.12L Cr | 24.97 | 4.15 | 21.20 | 21.10 | 0.00 | Above FV |
| Laurus Labs Limited | ₹ 1,969.00 | ₹ 1.06L Cr | 97.33 | 20.06 | 18.30 | 17.80 | 0.00 | Above FV |
| Lupin Limited | ₹ 2,095.00 | ₹ 95,797 Cr | 17.35 | 4.27 | 28.70 | 29.90 | 0.00 | Above FV |
| Mankind Pharma Limited | ₹ 2,280.00 | ₹ 94,174 Cr | 46.09 | 5.77 | 13.10 | 13.50 | 0.00 | Above FV |
| Dr. Reddy S Laboratories | ₹ 1,165.50 | ₹ 97,085 Cr | 29.30 | 2.53 | 11.20 | 13.00 | 0.70 | Above FV |
| Aurobindo Pharma Ltd | ₹ 1,679.80 | ₹ 96,652 Cr | 26.22 | 2.57 | 10.10 | 12.90 | 0.00 | Above FV |
| Glenmark Pharmaceuticals | ₹ 2,419.20 | ₹ 68,276 Cr | 37.94 | 6.49 | 23.60 | 39.80 | 0.10 | Above FV |
| Biocon Limited. | ₹ 390.65 | ₹ 63,609 Cr | 113.23 | 1.86 | 1.40 | 3.61 | 0.00 | Above FV |
Price, market cap, P/E, P/B and dividend yield reflect the live quote (delayed, cached 15 min); ROE/ROCE from reported financials. The highlighted row is the current company. Click a column header to sort. Educational data only.
How to read the peer comparison
This table places the company beside others in the same industry on a few common measures. Comparison adds context that a single company's numbers cannot give on their own.
- Valuation multiples like P/E and P/B are most meaningful within the same industry, because different industries naturally trade at different levels. Comparing a company only to its peers is more useful than to the whole market.
- Return measures (ROE, ROCE) show how efficiently each company turns capital into profit. A company well ahead of or behind its peers here is worth understanding.
- No single column decides anything. A beginner reads the row across — valuation, returns, and size together — and treats the highlighted current company as one data point among its peers.
- Use the sortable headers to rank peers on any measure, but remember that "cheaper" or "higher" on one metric is a starting question, not an answer.
Educational only — not a recommendation to buy, sell, or hold any security.